← Eichor
Study identifier: NCT06902142 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Prospective Multicenter Study of the Relationship Between Virological Effectiveness and Compliance in HIV-1-infected Patients Treated With Bictegravir

Condition: HIV Antiretroviral Therapy (ART) Adherence  ·  Sponsor: Association pour la promotion de la recherche en maladies infectieuses et tropicales dans le Loiret

PhaseN/A
Planned participants120
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Modern once-daily antiretroviral therapies have evolved considerably, improving patients' quality of life. However, sub-optimal adherence to antiretroviral therapy (ART) can lead to insufficient viral suppression and the emergence of resistant HIV strains. In particular, several populations encountered in HIV clinical practice face obstacles to optimal adherence. The investigators propose the prospective multicenter cohort study BICTECAPS, evaluating the effectiveness of the combination therapy bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in routine practice. The investigators hypothesize that the pharmacokinetic profile and genetic barrier provided by B/F/TAF will enable a high rate of virological suppression at low to moderate levels of adherence, probably 100% virological suppression above 70% adherence. The study is planned to include 120 patients with HIV infection treated with B/F/TAF, over a planned 2-year period with usual follow-up. The aim of this work is to evaluate virological suppression rates at 6 and 12 months according to adherence levels defined by electronic antiretroviral monitoring caps (MEMS caps) and by intra-cellular TAF assay on blotting paper (dried blood spot, DBS). The investigators hope to generate real-life data on B/F/TAF use from population groups generally under-represented in clinical trials, including robust measurements of adherence patterns using MEMS caps and DBS. . Key words : HIV-1 ; B/F/TAF ; Adherence ; Forgiveness

This description comes directly from the study's public registry record.

Talk to the study team

Laurent HOCQUELOUX, M.D.  ·  +33 2 38 22 95 88  ·  laurent.hocqueloux@chu-orleans.fr

Always discuss trial participation with your own doctor first.

Locations (8)

CHU de CaenCaen, FranceRecruiting
CHD VendéeLa Roche-sur-Yon, FranceNot Yet Recruiting
Hôpitaux Civils de LyonLyon, FranceNot Yet Recruiting
CHU de NantesNantes, FranceNot Yet Recruiting
CH de NiortNiort, FranceNot Yet Recruiting
CHU d'OrléansOrléans, FranceRecruiting
CHU Pitié-SalpétrièreParis, FranceNot Yet Recruiting
CHU de PoitiersPoitiers, FranceNot Yet Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06902142